Biofrontera AG (B8FK.DE)
40 additional metrics available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 30 | 29 | 26 | 32 | N/A | 13 | 8 | 71 |
| Operating profit | €m | ||||||||
| Net profit | €m | -13 | 38 | -44 | -0 | N/A | -4 | 2 | 13 |
| EPS reported | € | ||||||||
| Operating cashflow per share | € | ||||||||
| Capex per share | € | ||||||||
| FCF per share | € | ||||||||
| Free cash flow | €m | ||||||||
| Net debt | €m | ||||||||
| Book value equity | €m | ||||||||
| Book value per share | € | ||||||||
| Number of shares | m | ||||||||
| DPS (TTM paid) | € |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | ||||||||
| P/B LTM | x | ||||||||
| P/S LTM | x | ||||||||
| P/FCF LTM | x | ||||||||
| EV/EBITDA LTM | x | ||||||||
| EV/Sales LTM | x | ||||||||
| Earnings Yield LTM | % | ||||||||
| FCF Yield | % | ||||||||
| Quality | |||||||||
| ROE | % | ||||||||
| ROIC | % | ||||||||
| Operating margin | % | ||||||||
| Gross margin | % | ||||||||
| FCF/Sales | % | ||||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | ||||||||
| Sales Growth YoY | % | ||||||||
| Net Income Growth YoY | % | ||||||||
| FCF Growth | % | ||||||||
| Operating Profit Growth | % | ||||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | ||||||||
| Dividend Growth | % | ||||||||
| Payout Ratio | % | ||||||||
| FCF/Debt | x | ||||||||
| Net Debt/EBITDA | x | ||||||||
| EBIT/Net interest | x | ||||||||
| Net debt/market cap | % | ||||||||
| Net debt/Equity | % | ||||||||
| Gross debt/equity | % | ||||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free